Skip to content

Decoy Therapeutics Inc.: 10-K filed 2018-03-07

What Decoy Therapeutics Inc. reported in its annual report filed 2018-03-07 (fiscal FY 2017): 34 published measures, 126 facts as tagged in accession 0001615219-18-000018.

This filing

Form
10-K (annual report)
Filed
2018-03-07
Fiscal period
fiscal FY 2017
Accession
0001615219-18-000018 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Decoy Therapeutics Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2017-12-3134,992,772USD
At 2016-12-3163,214,979USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2017-12-315,886,884USD
At 2016-12-313,897,593USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2017-12-3129,105,888USD
At 2016-12-3159,317,386USD
At 2015-12-3192,192,408USD
At 2014-12-31-6,538,340USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2017-10-01 to 2017-12-31-8,028,531USD92
2017-01-01 to 2017-12-31-34,433,662USD365
2017-07-01 to 2017-09-30-9,332,113USD92
2017-04-01 to 2017-06-30-8,804,623USD91
2017-01-01 to 2017-03-31-8,268,395USD90
2016-10-01 to 2016-12-31-7,900,035USD92
2016-01-01 to 2016-12-31-39,493,123USD366
2016-07-01 to 2016-09-30-10,637,494USD92
2016-04-01 to 2016-06-30-11,363,133USD91
2016-01-01 to 2016-03-31-9,592,461USD91
2015-01-01 to 2015-12-31-29,141,630USD365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2017-01-01 to 2017-12-31-27,722,198USD365
2016-01-01 to 2016-12-31-32,051,873USD366
2015-01-01 to 2015-12-31-20,746,118USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2017-01-01 to 2017-12-31113,498USD365
2016-01-01 to 2016-12-31559,378USD366
2015-01-01 to 2015-12-31265,617USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2017-01-01 to 2017-12-312,632USD365
2016-01-01 to 2016-12-3122,098USD366
2015-01-01 to 2015-12-3180,843,751USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2017-01-01 to 2017-12-3124,489,562USD365
2016-01-01 to 2016-12-31-12,240,880USD366
2015-01-01 to 2015-12-31-27,265,091USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2017-12-31-111,079,275USD
At 2016-12-31-76,645,613USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2017-12-31331,040USD
At 2016-12-31556,315USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2017-01-01 to 2017-12-314,219,165USD365
2016-01-01 to 2016-12-316,572,963USD366
2015-01-01 to 2015-12-316,597,359USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2017-10-01 to 2017-12-31-8,092,960USD92
2017-01-01 to 2017-12-31-34,725,626USD365
2017-07-01 to 2017-09-30-9,409,452USD92
2017-04-01 to 2017-06-30-8,876,965USD91
2017-01-01 to 2017-03-31-8,346,249USD90
2016-10-01 to 2016-12-31-7,984,267USD92
2016-01-01 to 2016-12-31-39,886,232USD366
2016-07-01 to 2016-09-30-10,735,220USD92
2016-04-01 to 2016-06-30-11,470,951USD91
2016-01-01 to 2016-03-31-9,695,794USD91
2015-01-01 to 2015-12-31-29,213,658USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2017-12-3134,535,137USD
At 2016-12-3162,467,269USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2017-12-315,847,670USD
At 2016-12-313,889,195USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2017-12-312,004,440USD
At 2016-12-311,192,183USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2017-12-3110,385USD
At 2016-12-3112,181USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2017-10-01 to 2017-12-318,375,788USD92
2017-01-01 to 2017-12-3136,000,125USD365
2017-07-01 to 2017-09-309,823,053USD92
2017-04-01 to 2017-06-309,212,488USD91
2017-01-01 to 2017-03-318,588,796USD90
2016-10-01 to 2016-12-318,283,171USD92
2016-01-01 to 2016-12-3140,896,895USD366
2016-07-01 to 2016-09-3011,334,294USD92
2016-04-01 to 2016-06-3011,583,636USD91
2016-01-01 to 2016-03-319,695,794USD91
2015-01-01 to 2015-12-3129,213,658USD365

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2017-12-31431,891USD
At 2016-12-31454,132USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2017-10-01 to 2017-12-314,259,357USD92
2017-01-01 to 2017-12-3116,989,911USD365
2017-07-01 to 2017-09-304,739,360USD92
2017-04-01 to 2017-06-304,076,220USD91
2017-01-01 to 2017-03-313,914,974USD90
2016-10-01 to 2016-12-314,230,804USD92
2016-01-01 to 2016-12-3120,378,161USD366
2016-07-01 to 2016-09-305,665,357USD92
2016-04-01 to 2016-06-306,094,921USD91
2016-01-01 to 2016-03-314,387,079USD91
2015-01-01 to 2015-12-3112,749,379USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2017-12-3117,797,178shares
At 2016-12-3116,773,798shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2017-12-31140,184,630USD
At 2016-12-31135,962,935USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2017-12-31-1,247USD
At 2016-12-31-1,614USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2017-12-31953,923USD
At 2016-12-31879,329USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2017-12-31622,883USD
At 2016-12-31323,014USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2017-12-310USD
At 2016-12-3164,800USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2017-12-31777,102USD
At 2016-12-31925,983USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2017-12-314,490USD
At 2016-12-3126,927USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2017-01-01 to 2017-12-31-34,433,295USD365
2016-01-01 to 2016-12-31-39,470,083USD366
2015-01-01 to 2015-12-31-29,166,284USD365

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2017-01-01 to 2017-12-31-34,433,662USD365
2016-01-01 to 2016-12-31-39,493,123USD366
2015-01-01 to 2015-12-31-29,141,630USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2017-10-01 to 2017-12-313,983,088USD92
2017-01-01 to 2017-12-3118,503,684USD365
2017-07-01 to 2017-09-304,934,937USD92
2017-04-01 to 2017-06-304,990,943USD91
2017-01-01 to 2017-03-314,594,716USD90
2016-10-01 to 2016-12-313,918,661USD92
2016-01-01 to 2016-12-3119,855,987USD366
2016-07-01 to 2016-09-305,447,847USD92
2016-04-01 to 2016-06-305,377,784USD91
2016-01-01 to 2016-03-315,111,695USD91
2015-01-01 to 2015-12-3116,464,279USD365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2017-01-01 to 2017-12-31324,548USD365
2016-01-01 to 2016-12-31277,231USD366
2015-01-01 to 2015-12-3149,881USD365

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2017-01-01 to 2017-12-31-1,796USD365
2016-01-01 to 2016-12-3112,181USD366
2015-01-01 to 2015-12-310USD365

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2017-01-01 to 2017-12-31-22,241USD365
2016-01-01 to 2016-12-31454,132USD366
2015-01-01 to 2015-12-310USD365

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2017-01-01 to 2017-12-31819,357USD365
2016-01-01 to 2016-12-31309,437USD366
2015-01-01 to 2015-12-31621,393USD365

Inspect the source

Entity
Decoy Therapeutics Inc. / CIK 0001615219
Captured
2026-09-21T17:20:32.388Z
SEC response SHA-256
3dae29679ef228e32bff301a79640d7e283fcc5b87c08a4882faedfce1c66e98

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001615219.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))